Lipid Screening in HIV-Infected Veterans

Philip (Todd) Korthuis, Steven M. Asch, Henry D. Anaya, Hal Morgenstern, Matthew Bidwell Goetz, Elizabeth M. Yano, Lisa V. Rubenstein, Martin L. Lee, Samuel A. Bozzette

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Lipid screening is recommended for patients taking protease inhibitors (PIs). Methods: We examined data from the Veterans Administration Immunology Case Registry to assess lipid screening among HIV-infected veterans who received PIs for at least 6 consecutive months during 1999 and 2001. We estimated crude and adjusted associations between lipid screening and patient characteristics (age, gender, HIV exposure, and race/ethnicity), comorbidities (AIDS, cardiovascular disease, diabetes, hypertension, smoking, and hyperlipidemia), and facility characteristics (urban location, case management, guidelines, and quality improvement programs). Results: Among 4065 patients on PIs, clinicians screened 2395 (59%) for lipids within 6 months of initiating treatment. Adjusting for patient characteristics, comorbidities, facility traits, and clustering, lipid screening was more common among patients who were cared for in urban areas (relative risk [RR] = 1.3, confidence limits: 1.0-1.5), diabetic (RR = 1.2, confidence limits: 1.1-1.3), or previously hyperlipidemic (RR = 1.4, confidence limits: 1.3-1.5) and less common among patients with a history of intravenous drug use (IVDU) (RR = 0.90, confidence limits: 0.79-1.0) or unknown HIV risk (RR = 0.85, confidence limits: 0.75-0.95). Conclusions: Six in 10 patients taking PIs receive lipid screening within 6 months of PI use. Systemic interventions to improve overall HIV quality of care should also address lipid screening, particularly among patients with unknown or IVDU HIV risk and those cared for in nonurban areas.

Original languageEnglish (US)
Pages (from-to)253-260
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes
Volume35
Issue number3
DOIs
StatePublished - Mar 1 2004

Fingerprint

Veterans
HIV
Lipids
Protease Inhibitors
Comorbidity
United States Department of Veterans Affairs
Quality of Health Care
Case Management
Quality Improvement
Allergy and Immunology
Hyperlipidemias
Pharmaceutical Preparations
Cluster Analysis
Registries
Acquired Immunodeficiency Syndrome
Cardiovascular Diseases
Smoking
Guidelines
Hypertension

Keywords

  • AIDS
  • HIV
  • Hyperlipidemia
  • Protease inhibitors
  • Quality of health care

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Korthuis, P. T., Asch, S. M., Anaya, H. D., Morgenstern, H., Goetz, M. B., Yano, E. M., ... Bozzette, S. A. (2004). Lipid Screening in HIV-Infected Veterans. Journal of Acquired Immune Deficiency Syndromes, 35(3), 253-260. https://doi.org/10.1097/00126334-200403010-00005

Lipid Screening in HIV-Infected Veterans. / Korthuis, Philip (Todd); Asch, Steven M.; Anaya, Henry D.; Morgenstern, Hal; Goetz, Matthew Bidwell; Yano, Elizabeth M.; Rubenstein, Lisa V.; Lee, Martin L.; Bozzette, Samuel A.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 35, No. 3, 01.03.2004, p. 253-260.

Research output: Contribution to journalArticle

Korthuis, PT, Asch, SM, Anaya, HD, Morgenstern, H, Goetz, MB, Yano, EM, Rubenstein, LV, Lee, ML & Bozzette, SA 2004, 'Lipid Screening in HIV-Infected Veterans', Journal of Acquired Immune Deficiency Syndromes, vol. 35, no. 3, pp. 253-260. https://doi.org/10.1097/00126334-200403010-00005
Korthuis, Philip (Todd) ; Asch, Steven M. ; Anaya, Henry D. ; Morgenstern, Hal ; Goetz, Matthew Bidwell ; Yano, Elizabeth M. ; Rubenstein, Lisa V. ; Lee, Martin L. ; Bozzette, Samuel A. / Lipid Screening in HIV-Infected Veterans. In: Journal of Acquired Immune Deficiency Syndromes. 2004 ; Vol. 35, No. 3. pp. 253-260.
@article{c6c20f3564254ac0a79865ebdb84ca43,
title = "Lipid Screening in HIV-Infected Veterans",
abstract = "Background: Lipid screening is recommended for patients taking protease inhibitors (PIs). Methods: We examined data from the Veterans Administration Immunology Case Registry to assess lipid screening among HIV-infected veterans who received PIs for at least 6 consecutive months during 1999 and 2001. We estimated crude and adjusted associations between lipid screening and patient characteristics (age, gender, HIV exposure, and race/ethnicity), comorbidities (AIDS, cardiovascular disease, diabetes, hypertension, smoking, and hyperlipidemia), and facility characteristics (urban location, case management, guidelines, and quality improvement programs). Results: Among 4065 patients on PIs, clinicians screened 2395 (59{\%}) for lipids within 6 months of initiating treatment. Adjusting for patient characteristics, comorbidities, facility traits, and clustering, lipid screening was more common among patients who were cared for in urban areas (relative risk [RR] = 1.3, confidence limits: 1.0-1.5), diabetic (RR = 1.2, confidence limits: 1.1-1.3), or previously hyperlipidemic (RR = 1.4, confidence limits: 1.3-1.5) and less common among patients with a history of intravenous drug use (IVDU) (RR = 0.90, confidence limits: 0.79-1.0) or unknown HIV risk (RR = 0.85, confidence limits: 0.75-0.95). Conclusions: Six in 10 patients taking PIs receive lipid screening within 6 months of PI use. Systemic interventions to improve overall HIV quality of care should also address lipid screening, particularly among patients with unknown or IVDU HIV risk and those cared for in nonurban areas.",
keywords = "AIDS, HIV, Hyperlipidemia, Protease inhibitors, Quality of health care",
author = "Korthuis, {Philip (Todd)} and Asch, {Steven M.} and Anaya, {Henry D.} and Hal Morgenstern and Goetz, {Matthew Bidwell} and Yano, {Elizabeth M.} and Rubenstein, {Lisa V.} and Lee, {Martin L.} and Bozzette, {Samuel A.}",
year = "2004",
month = "3",
day = "1",
doi = "10.1097/00126334-200403010-00005",
language = "English (US)",
volume = "35",
pages = "253--260",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Lipid Screening in HIV-Infected Veterans

AU - Korthuis, Philip (Todd)

AU - Asch, Steven M.

AU - Anaya, Henry D.

AU - Morgenstern, Hal

AU - Goetz, Matthew Bidwell

AU - Yano, Elizabeth M.

AU - Rubenstein, Lisa V.

AU - Lee, Martin L.

AU - Bozzette, Samuel A.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Background: Lipid screening is recommended for patients taking protease inhibitors (PIs). Methods: We examined data from the Veterans Administration Immunology Case Registry to assess lipid screening among HIV-infected veterans who received PIs for at least 6 consecutive months during 1999 and 2001. We estimated crude and adjusted associations between lipid screening and patient characteristics (age, gender, HIV exposure, and race/ethnicity), comorbidities (AIDS, cardiovascular disease, diabetes, hypertension, smoking, and hyperlipidemia), and facility characteristics (urban location, case management, guidelines, and quality improvement programs). Results: Among 4065 patients on PIs, clinicians screened 2395 (59%) for lipids within 6 months of initiating treatment. Adjusting for patient characteristics, comorbidities, facility traits, and clustering, lipid screening was more common among patients who were cared for in urban areas (relative risk [RR] = 1.3, confidence limits: 1.0-1.5), diabetic (RR = 1.2, confidence limits: 1.1-1.3), or previously hyperlipidemic (RR = 1.4, confidence limits: 1.3-1.5) and less common among patients with a history of intravenous drug use (IVDU) (RR = 0.90, confidence limits: 0.79-1.0) or unknown HIV risk (RR = 0.85, confidence limits: 0.75-0.95). Conclusions: Six in 10 patients taking PIs receive lipid screening within 6 months of PI use. Systemic interventions to improve overall HIV quality of care should also address lipid screening, particularly among patients with unknown or IVDU HIV risk and those cared for in nonurban areas.

AB - Background: Lipid screening is recommended for patients taking protease inhibitors (PIs). Methods: We examined data from the Veterans Administration Immunology Case Registry to assess lipid screening among HIV-infected veterans who received PIs for at least 6 consecutive months during 1999 and 2001. We estimated crude and adjusted associations between lipid screening and patient characteristics (age, gender, HIV exposure, and race/ethnicity), comorbidities (AIDS, cardiovascular disease, diabetes, hypertension, smoking, and hyperlipidemia), and facility characteristics (urban location, case management, guidelines, and quality improvement programs). Results: Among 4065 patients on PIs, clinicians screened 2395 (59%) for lipids within 6 months of initiating treatment. Adjusting for patient characteristics, comorbidities, facility traits, and clustering, lipid screening was more common among patients who were cared for in urban areas (relative risk [RR] = 1.3, confidence limits: 1.0-1.5), diabetic (RR = 1.2, confidence limits: 1.1-1.3), or previously hyperlipidemic (RR = 1.4, confidence limits: 1.3-1.5) and less common among patients with a history of intravenous drug use (IVDU) (RR = 0.90, confidence limits: 0.79-1.0) or unknown HIV risk (RR = 0.85, confidence limits: 0.75-0.95). Conclusions: Six in 10 patients taking PIs receive lipid screening within 6 months of PI use. Systemic interventions to improve overall HIV quality of care should also address lipid screening, particularly among patients with unknown or IVDU HIV risk and those cared for in nonurban areas.

KW - AIDS

KW - HIV

KW - Hyperlipidemia

KW - Protease inhibitors

KW - Quality of health care

UR - http://www.scopus.com/inward/record.url?scp=1442348465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442348465&partnerID=8YFLogxK

U2 - 10.1097/00126334-200403010-00005

DO - 10.1097/00126334-200403010-00005

M3 - Article

VL - 35

SP - 253

EP - 260

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -